Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Aytu Biopharma (AYTU) Income towards Parent Company: 2009-2025

Historic Income towards Parent Company for Aytu Biopharma (AYTU) over the last 17 years, with Sep 2025 value amounting to $2.0 million.

  • Aytu Biopharma's Income towards Parent Company rose 415.75% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 195.99%. This contributed to the annual value of $620,000 for FY2025, which is 118.65% up from last year.
  • As of Q3 2025, Aytu Biopharma's Income towards Parent Company stood at $2.0 million, which was up 3,069.35% from $62,000 recorded in Q2 2025.
  • Aytu Biopharma's 5-year Income towards Parent Company high stood at $2.0 million for Q3 2025, and its period low was -$53.3 million during Q1 2022.
  • Moreover, its 3-year median value for Income towards Parent Company was -$599,000 (2024), whereas its average is -$956,545.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first plummeted by 546.80% in 2021, then surged by 415.75% in 2025.
  • Aytu Biopharma's Income towards Parent Company (Quarterly) stood at -$11.5 million in 2021, then surged by 42.04% to -$6.7 million in 2022, then surged by 87.46% to -$839,000 in 2023, then skyrocketed by 114.66% to $123,000 in 2024, then surged by 415.75% to $2.0 million in 2025.
  • Its Income towards Parent Company was $2.0 million in Q3 2025, compared to $62,000 in Q2 2025 and $54,000 in Q1 2025.